JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gully, D.
Right arrow Articles by Maffrand, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gully, D.
Right arrow Articles by Maffrand, J. P.

Vol. 280, Issue 2, 802-812, 1997

Biochemical and Pharmacological Activities of SR 142948A, a New Potent Neurotensin Receptor Antagonist

Danielle Gully, Bernard Labeeuw, Robert Boigegrain, Florence Oury-Donat, André Bachy, Martine Poncelet, Régis Steinberg, Marie Françoise Suaud-Chagny, Vincent Santucci, Natalio Vita, Florence Pecceu, Catherine Labbé-Jullié, Patrick Kitabgi, Philippe Soubrié, Gérard Le Fur and Jean Pierre Maffrand

Sanofi Recherche, Toulouse (D.G., A.B., N.V., F.P., G.L.F., J.P.M.), Sanofi Recherche, Montpellier (B.L., R.B., F.O.-D., M.P., R.S., V.S., P.S.), INSERM Création Jeune Formation 95-06, Université Claude Bernard Lyon I, Lyon (M.F.S.-C.), and Institut de Pharmacologie Moléculaire et Cellulaire-CNRS, Sophia Antipolis, Valbonne (C.L.-J., P.K.), France

SR 142948A, 2-{[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methylcarbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]amino}adamantane-2-carboxylic acid, hydrochloride, a new and extremely potent neurotensin (NT) receptor antagonist, has been characterized in comparison with SR 48692. This selective compound possesses nanomolar affinities for NT receptors, recognizes the two binding sites described for the NT receptor and fully displaces [3H]SR 48692 specific binding. SR 142948A antagonizes the classical in vitro NT effects, i.e., inositol monophosphate formation in HT 29 cells (IC50 = 3.9 nM) or intracellular calcium mobilization in Chinese hamster ovary cells transfected with the human receptor. It dose-dependently (0.04-640 × 10-3 mg/kg p.o.) inhibits the turning behavior induced by unilateral intrastriatal injection of NT in mice, with the biphasic profile previously seen for SR 48692. At 0.1 mg/kg (i.p.), it completely antagonizes NT-evoked acetylcholine release in the rat striatum. In contrast to SR 48692, SR 142948A (p.o.) blocks both hypothermia and analgesia induced by i.c.v. injection of NT (mice and/or rats) but is unable to modify the dopamine release evoked by NT injection into the ventral tegmental area. In summary, SR 142948A retains the properties of the lead compound SR 48692 (no intrinsic agonist activity, oral bioavailability, long duration of action and good brain access), reveals a wider spectrum of activity than SR 48692 (probably due to the inhibition of NT receptor subtypes) and represents an additional tool for further exploration of the therapeutic potential of this class of compounds.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Cereb CortexHome page
T. Antonelli, M. C. Tomasini, J. Fournier, R. Mazza, S. Tanganelli, S. Pirondi, K. Fuxe, and F. Luca
Neurotensin Receptor Involvement in the Rise of Extracellular Glutamate Levels and Apoptotic Nerve Cell Death in Primary Cortical Cultures after Oxygen and Glucose Deprivation
Cereb Cortex, August 1, 2008; 18(8): 1748 - 1757.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
S. Grimond-Billa, C Norman, G. Bennett, and H. Cassaday
Selectively increased trace conditioning under the neurotensin agonist PD 149163 in an aversive procedure in which SR 142948A was without intrinsic effect
J Psychopharmacol, May 1, 2008; 22(3): 290 - 299.
[Abstract] [PDF]

Home page
 J. Neurosci.Home page
P. Sarret, M. J. Esdaile, A. Perron, J. Martinez, T. Stroh, and A. Beaudet
Potent Spinal Analgesia Elicited through Stimulation of NTS2 Neurotensin Receptors
J. Neurosci., September 7, 2005; 25(36): 8188 - 8196.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
J H Li, F Sicard, M A Salam, M Baek, J LePrince, H Vaudry, K Kim, H B Kwon, and J Y Seong
Molecular cloning and functional characterization of a type-I neurotensin receptor (NTR) and a novel NTR from the bullfrog brain
J. Mol. Endocrinol., June 1, 2005; 34(3): 793 - 807.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Bracci, C. Falciani, B. Lelli, L. Lozzi, Y. Runci, A. Pini, M. G. De Montis, A. Tagliamonte, and P. Neri
Synthetic Peptides in the Form of Dendrimers Become Resistant to Protease Activity
J. Biol. Chem., November 21, 2003; 278(47): 46590 - 46595.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. J. Pettibone, J. F. Hess, P. J. Hey, M. A. Jacobson, M. Leviten, E. V. Lis, P. J. Mallorga, D. M. Pascarella, M. A. Snyder, J. B. Williams, et al.
The Effects of Deleting the Mouse Neurotensin Receptor NTR1 on Central and Peripheral Responses to Neurotensin
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 305 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
E. B. Binder, B. Kinkead, M. J. Owens, and C. B. Nemeroff
Neurotensin and Dopamine Interactions
Pharmacol. Rev., December 1, 2001; 53(4): 453 - 486.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Azriel and E. Burcher
Characterization and Autoradiographic Localization of Neurotensin Binding Sites in Human Sigmoid Colon
J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1074 - 1081.
[Abstract] [Full Text]

Home page
 J. Neurophysiol.Home page
A. H. Li, H.-M. Hwang, P. P. Tan, T. Wu, and H.-L. Wang
Neurotensin Excites Periaqueductal Gray Neurons Projecting to the Rostral Ventromedial Medulla
J Neurophysiol, April 1, 2001; 85(4): 1479 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
E. B. Binder, B. Kinkead, M. J. Owens, C. D. Kilts, and C. B. Nemeroff
Enhanced Neurotensin Neurotransmission Is Involved in the Clinically Relevant Behavioral Effects of Antipsychotic Drugs: Evidence from Animal Models of Sensorimotor Gating
J. Neurosci., January 15, 2001; 21(2): 601 - 608.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. J. Smith, A. A. Hawranko, P. J. Monroe, D. Gully, M. O. Urban, C. R. Craig, J. P. Smith, and D. L. Smith
Dose-Dependent Pain-Facilitatory and -Inhibitory Actions of Neurotensin Are Revealed by SR 48692, a Nonpeptide Neurotensin Antagonist: Influence on the Antinociceptive Effect of Morphine,
J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 899 - 908.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.